ATE419006T1 - Multivalenter dengue-virus impfstoff - Google Patents

Multivalenter dengue-virus impfstoff

Info

Publication number
ATE419006T1
ATE419006T1 AT00919748T AT00919748T ATE419006T1 AT E419006 T1 ATE419006 T1 AT E419006T1 AT 00919748 T AT00919748 T AT 00919748T AT 00919748 T AT00919748 T AT 00919748T AT E419006 T1 ATE419006 T1 AT E419006T1
Authority
AT
Austria
Prior art keywords
dengue
virus
dengue virus
virus vaccine
attenuated
Prior art date
Application number
AT00919748T
Other languages
English (en)
Inventor
Kenneth Eckels
Joseph Putnak
Doria Dubois
Bruce Innis
Charles Hoke
Sun Wellington
Kanesa-Thasan Niranjan
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Application granted granted Critical
Publication of ATE419006T1 publication Critical patent/ATE419006T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00919748T 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff ATE419006T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12631399P 1999-03-26 1999-03-26
US18172400P 2000-02-11 2000-02-11

Publications (1)

Publication Number Publication Date
ATE419006T1 true ATE419006T1 (de) 2009-01-15

Family

ID=26824502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919748T ATE419006T1 (de) 1999-03-26 2000-03-24 Multivalenter dengue-virus impfstoff

Country Status (12)

Country Link
US (2) US6638514B1 (de)
EP (1) EP1165127B1 (de)
JP (1) JP2002540168A (de)
KR (1) KR100721745B1 (de)
CN (1) CN1191092C (de)
AT (1) ATE419006T1 (de)
AU (1) AU779280B2 (de)
CA (1) CA2368674A1 (de)
DE (1) DE60041250D1 (de)
ES (1) ES2322327T3 (de)
MX (1) MXPA01009683A (de)
WO (1) WO2000057907A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
EP1402075B1 (de) 2001-05-22 2012-11-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Entwicklung von zur attenuierung von dengue-viren geeigneten mutationen und chimäre dengue-viren
WO2006134433A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
EP2376923A4 (de) * 2008-12-22 2012-08-15 Children S Res Inst Verfahren für den nachweis von sepsis
MX338898B (es) 2009-02-17 2016-05-03 Glaxosmithkline Biolog Sa Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
US9211323B2 (en) * 2009-06-01 2015-12-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
ES2436317T3 (es) 2010-05-07 2013-12-30 Deutsches Krebsforschungszentrum Parvovirus de roedor modificado capaz de propagarse y difundirse en gliomas humanos
MX366154B (es) 2013-06-21 2019-06-28 Merck Sharp & Dohme Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
MY192543A (en) 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
WO2017004567A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (de) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. Zusammensetzungen und verfahren zur therapie mit dengue-virus
US11655471B2 (en) 2017-03-08 2023-05-23 University Of Georgia Research Foundation, Inc. Engineered cells with decreased gene expression resulting in increased viral production
MX2019015194A (es) * 2017-06-15 2020-08-03 Primevax Immuno Oncology Inc Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181792A (ja) * 1992-06-05 1994-07-05 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法、およびそれに用いる組み換えウイルス
ATE196737T1 (de) * 1993-05-25 2000-10-15 American Cyanamid Co Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
WO1998018324A1 (en) * 1996-10-28 1998-05-07 The University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral rna
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine

Also Published As

Publication number Publication date
US20070087015A1 (en) 2007-04-19
CN1351502A (zh) 2002-05-29
JP2002540168A (ja) 2002-11-26
ES2322327T3 (es) 2009-06-19
KR20020008136A (ko) 2002-01-29
DE60041250D1 (de) 2009-02-12
MXPA01009683A (es) 2003-06-24
CN1191092C (zh) 2005-03-02
US6638514B1 (en) 2003-10-28
WO2000057907A2 (en) 2000-10-05
EP1165127A2 (de) 2002-01-02
AU4038200A (en) 2000-10-16
KR100721745B1 (ko) 2007-05-25
AU779280B2 (en) 2005-01-13
CA2368674A1 (en) 2000-10-05
EP1165127B1 (de) 2008-12-31
US7217418B2 (en) 2007-05-15
WO2000057907A3 (en) 2001-04-12
WO2000057907A9 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
DE60041250D1 (de) Multivalenter dengue-virus impfstoff
Tuiskunen Bäck et al. Dengue viruses–an overview
Nedjadi et al. Tackling dengue fever: Current status and challenges
MY192806A (en) Compositions and methods of vaccination against dengue virus in children and young adults
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
IL196815A0 (en) Hepatitis c virus inhibitors
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
NO20044897L (no) Hepatitt C virus inhibitorer
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
MY169275A (en) Method of immunization against the four serotypes of dengue
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
Li et al. Inhibition of Japanese encephalitis virus entry into the cells by the envelope glycoprotein domain III (EDIII) and the loop3 peptide derived from EDIII
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
JP2002540168A5 (de)
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
JP2016504315A5 (de)
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
EP1594509A4 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
Roberts et al. New opportunities for control of dengue virus
ATE456953T1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
Briggs et al. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties